FDA approves Merck's lung cancer drug as first-line treatmen
The drug has been approved for treating metastatic non-small cell lung cancer (NSCLC) patients with high-levels of a protein known for suppressing the immune system called PD-L1.

Keytruda works by taking the brakes off the immune system by blocking the interaction between PD-L1 and another protein, PD-1. The drug has already been approved for patients who have undergone previous chemotherapy for advanced non-small lung cancer...

I●●●●n Y●●●v and 4 others like this1 share